XML 67 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity (Tables)
 12 Months Ended
Mar. 31, 2022
Stockholders' Equity Note [Abstract]  
Schedule of shares repurchased over last three years
Information regarding share repurchase activity over the last three years is as follows:
Share Repurchases (1)
(In millions, except price per share data)
Total
Number of
Shares
Purchased (2)
Average Price
Paid Per Share		Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the
Programs
Balance, March 31, 2019$3,469 
Shares repurchased - Open market9.2 $144.68 (1,334)
Shares repurchased - May 2019 ASR4.7 $127.68 (600)
Balance, March 31, 20201,535 
Shares repurchase authorization increase in 20212,000 
Shares repurchased - Open market (3)
4.7 $160.33 (750)
Balance, March 31, 20212,785 
Shares repurchased - May 2021 ASR
5.2 $193.22 (1,000)
Shares repurchased - Open market4.6 $217.73 (1,007)
Shares repurchase authorization increase in 20224,000 
Shares repurchased - February 2022 ASR (4)
4.8 $265.56 (1,500)
Balance, March 31, 2022$3,278 
(1)This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards. It also excludes shares related to the Company’s Split-off of the Change Healthcare JV as described below.
(2)The number of shares purchased reflects rounding adjustments.
(3)Of the total dollar value, $8 million was accrued within “Other accrued liabilities” in the Company’s Consolidated Balance Sheet as of March 31, 2021 for share repurchases that were executed in late March and settled in early April.
(4)In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company’s common stock. The average price paid per share and total number of shares purchased under this program are estimates based on the initial share purchase price and initial delivery of shares under an ASR agreement and may differ from the average price paid per share and total number of shares purchased under the ASR program upon its final settlement in May 2022.
Schedule of accumulated other comprehensive income (loss)
Information regarding changes in the Company’s accumulated other comprehensive income (loss) by component are as follows:
Foreign Currency Translation Adjustments
(In millions)
Foreign Currency Translation Adjustments, Net of Tax (1)
Unrealized Gains (Losses) on Net Investment Hedges,
Net of Tax (2)
Unrealized Gains (Losses) on Cash Flow Hedges,
Net of Tax		Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive Loss
Balance at March 31, 2019$(1,628)$53 $(37)$(237)$(1,849)
Other comprehensive income (loss) before reclassifications
(151)85 86 33 53 
Amounts reclassified to earnings and
other (3)
— — — 96 96 
Other comprehensive income (loss)(151)85 86 129149 
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests1 — — 2 3 
Other comprehensive income (loss) attributable to McKesson
(152)85 86 127146 
Balance at March 31, 2020(1,780)138 49 (110)(1,703)
Other comprehensive income (loss) before reclassifications
312 (175)(36)(2)99 
Amounts reclassified to earnings and
other (4)
47 — — 24 71 
Other comprehensive income (loss)359 (175)(36)22 170 
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests(60)(1)— 8(53)
Other comprehensive income (loss) attributable to McKesson
419 (174)(36)14223 
Balance at March 31, 2021(1,361)(36)13 (96)(1,480)
Other comprehensive income (loss) before reclassifications
(51)41183139 
Amounts reclassified to earnings and other (5)
71 (1)(4)1076 
Other comprehensive income20 401441115 
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests5 (6)— — (1)
Other comprehensive income attributable to McKesson15461441116 
Exercise of put right by noncontrolling shareholders of McKesson Europe AG(158)— — (12)(170)
Balance at March 31, 2022$(1,504)$10 $27 $(67)$(1,534)
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Europe and Canada into the Company’s reporting currency, U.S. dollars.
(2)Amounts before reclassifications recorded in 2022, 2021, and 2020 include gains (losses) of $73 million, $(118) million, and $39 million, respectively, related to net investment hedges from Euro-denominated notes and gains (losses) of $(4) million, $(119) million, and $76 million, respectively, related to net investment hedges from cross-currency swaps. These amounts are net of income tax benefit (expense) of $(23) million, $62 million, and $(30) million in 2022, 2021, and 2020, respectively.
(3)Primarily reflects a reclassification of losses of $127 million, net of $33 million of income tax benefit, predominantly on the termination of the Company’s U.S. defined benefit pension plan from “Accumulated other comprehensive loss” to “Other income, net” in the Company’s Consolidated Statement of Operations.
(4)Primarily includes adjustments for amounts related to the contribution of the Company’s German pharmaceutical wholesale business to a joint venture, as discussed in more detail in Financial Note 2, “Held for Sale” and Financial Note 6, “Other Income, Net.” These amounts were included in the 2021 and 2020 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within Selling, distribution, general, and administrative expenses in the Consolidated Statements of Operations.
(5)Primarily includes adjustments for amounts related to the sale of the Company’s Austrian business, as discussed in more detail in Financial Note 2, “Held for Sale.” These amounts were included in the 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within Selling, distribution, general, and administrative expenses in the Consolidated Statement of Operations.